Hmmm. All is not well with the manufacturer of Suboxone.
Reckitt Benckiser’s offices in Richmond, Va., were raided by a team of IRS and Office of Inspector General (OIG) agents on December 3rd.
No one is saying what the feds are investigating, but here is some legal analysis.
The search warrant, which company officials say was issued from the U.S. Attorney’s Office for the District of Western Virginia, is a stunning development. When the Government decides to investigate a company, the normal practice is to issue a lengthy subpoena identifying the records it wants the company to produce. With the assistance of outside counsel, the company produces the records on a rolling basis and, at some point, there is a negotiated settlement involving civil and sometimes criminal charges.
On the other hand, a search warrant is normally issued and executed only when the prospective charges are quite serious and, more importantly, when the Government strongly suspects that records may be destroyed and simply can’t trust the company to comply with the subpoena. Although we can’t speculate on the criminal charges the Government may be contemplating, we can be fairly certain that Reckitt and at least a few of its executives are facing some tough times ahead.
via Feds raid Reckitt Benckiser offices; criminal probe underway – Lexology.
A major treatment provider, Caron, weighs in on Hazelden’s adoption of buprenorphine maintenance treatment:
We use buprenorphine (Suboxone) to assist with the detoxification process from opioids and the length of time can vary depending on the patient’s progress and additional medical issues, such as chronic pain. However, unlike Hazelden’s goal as stated in the article, Caron’s treatment goal is to completely withdraw the patient from buprenorphine. We do not use burprenophine as an ongoing maintenance medication. Caron has been treating addicts and their families for more than 50 years and our evidence-based practices show that treatment requires medical, physical, behavioral, spiritual and psychological intervention.
At this time, we don’t believe there is sufficient evidence that remaining on a controlled substance, like buprenorphine, for the long term is a healthy approach to recovery. Instead, we focus on the critical role the 12-Steps play in helping individuals and families achieve and retain long-term sobriety and wellness.
It’s going to be interesting to see where the lines get drawn.
One neglected fact is that there are treatment programs that have already gone the buprenorphine maintenance route and abandoned it because the outcome did not resemble recovery and clients and their families were not satisfied.